[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597007":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":34,"collaborators":10,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":10,"enrollmentInfo":47,"targetDuration":10,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":63,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Royal North Shore Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients with glioblastoma receiving Bevacizumab as part of their standard of care",null,[12],"Diagnostic Test: PSMA PET\u002FCT scan",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","PSMA PET\u002FCT scan","PSMA PET scan will be used to monitor changes in PSMA expression in response to bevacizumab.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Alexander Yuile","CONTACT","+61 2 94631171","Alexander.Yuile@health.nsw.gov.au",[26],{"facility":5,"status":10,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":10,"geoPoint":10,"contacts":32},"Saint Leonards","New South Wales","2065","Australia","AU",[33],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":35,"investigatorFullName":21,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Principal Investigator","100597007","the-effect-of-glioblastoma-psma-expression-following-tumour-vegf-blockade-from-bevacizumab-100597007",false,"NCT07052877","The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab","Investigating Glioblastoma PSMA Expression by Utilizing Anti-VEGF and Its Effect on PSMA PET Scan Avidity","GUAVA","Inclusion Criteria:\n\n* \\> 18 year of age\n* ECOG 0-2\n* Able to provide informed consent for the study\n* Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour\n* Confirmed glioblastoma IDH1\u002F2 wildtype (WHO2021)\n* For bevacizumab treatment as per treating physician\n* Able to comply with trial requirements\n\nExclusion Criteria:\n\n* No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment)\n* Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope\n* Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging\n* Does not fulfill PBS requirements for bevacizumab\n* Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study","ALL","18 Years",{"count":48,"type":49},20,"ESTIMATED","OBSERVATIONAL","This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.",[53,54],"Glioblastoma","Glioblastoma Multiforme (GBM)",[56,57,58,59,60,61,62],"glioblastoma","anti-VEGF","PSMA","bevacizumab","VEGF","glioma","astrocytoma","NOT_YET_RECRUITING","2025-07-08",{"date":66,"type":67},"2025-07-11","ACTUAL",{"date":69,"type":49},"2025-07",{"date":71,"type":49},"2027-07",{"name":5,"class":6},1]